▲ +111.99% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Wave Life Sciences in the last 3 months. The average price target is $19.14, with a high forecast of $27.00 and a low forecast of $10.00. The average price target represents a 111.99% upside from the last price of $9.03.
The current consensus among 7 investment analysts is to buy stock in Wave Life Sciences. This Buy consensus rating has held steady for over two years.
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on programs in neurology in the central nervous system and neuromuscular system. The company has a research, license, and option agreement with Pfizer Inc. and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of stereopure oligonucleotide therapeutics and oligonucleotide therapeutics; and research, development, and develop antisense oligonucleotides. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.